Lorazepam

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Epilepsy
NCT01870024 · Assistance Publique - Hôpitaux de Paris
2013-06-26 – 2018-02-23 · Status Epilepticus, Epilepsy
What this study did
NCT02134366 · The Cooper Health System
2014-07 – 2017-07 · Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
What this study did
NCT02239380 · Pfizer
2014-11 – 2016-08 · Status Epilepticus
What this study did
NCT00735527 · All India Institute of Medical Sciences
2008-05 – 2009-04 · Status Epilepticus, Seizures
What this study did
NCT00343096 · Kamuzu University of Health Sciences
2006-06 – 2009-03 · Status Epilepticus, Convulsions
What this study did
NCT00116064 · Kamuzu University of Health Sciences
2004-07 – 2005-06 · Status Epilepticus, Convulsions
What this study did
NCT00004297 · National Institute of Neurological Disorders and Stroke (NINDS)
1995-11 – 1999-02 · Status Epilepticus
What this study did
Other / comorbidity
NCT07017452 · University of Manitoba
2025-08 – 2026-06 · Benign Prostate Hypertrophy(BPH)
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT02305797 · Edgemont Pharmaceuticals, LLC
2015-01 – 2016-05 · Generalized Anxiety Disorder (GAD)
What this study did
NCT01901003 · Assistance Publique Hopitaux De Marseille
2012-11 – 2014-06 · Perioperative Anxiety
What this study did
NCT01827293 · Shahid Beheshti University of Medical Sciences
2013-04 – 2013-06 · Peripheral Vertigo.
What this study did
Phase 2/3 (4)
Epilepsy
NCT00621478 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2008-02 – 2012-05 · Status Epilepticus
What this study did
NCT00465244 · Massachusetts General Hospital
2008-01 – 2010-05 · Seizures
What this study did
Other / comorbidity
NCT03743649 · M.D. Anderson Cancer Center
2019-07-17 – 2028-12-31 · Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
What this study did
NCT00109395 · The Emmes Company, LLC
2004-09 – 2007-09 · Critical Illness
What this study did
Phase 2 (13)
Other / comorbidity
NCT01949662 · M.D. Anderson Cancer Center
2014-01 – 2028-01-01 · Advanced Cancers
What this study did
NCT05662228 · University of Colorado, Denver
2023-06-29 – 2026-05-28 · Down Syndrome, Regression
What this study did
NCT06496854 · University of Wisconsin, Madison
2025-10 – 2026-01 · Pain, IUD
What this study did
NCT04646135 · Bambino Gesù Hospital and Research Institute
2020-12 – 2021-12 · Analgesia
What this study did
NCT03756038 · Maria Pacella
2019-01-25 – 2019-03-27 · Acute Pain
What this study did
NCT03180632 · St. Justine's Hospital
2017-06-28 – 2018-06-01 · Anxiety
What this study did
NCT01790490 · New York State Psychiatric Institute
2011-02 – 2012-03 · Cocaine Dependence
What this study did
NCT00431184 · Mclean Hospital
2007-01 – 2011-03 · Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
What this study did
NCT00429702 · University of South Florida
2007-10 – 2009-11 · Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT00011297 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
est. completion 2005-12 · Alcoholism
What this study did
NCT00229125 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2001-07 – 2005-09 · Alcohol Withdrawal Syndrome(AWS)
What this study did
NCT00546624 · Merck Sharp & Dohme LLC
2002-11 – 2003-02 · Anxiety Disorder
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT00123578 · University of California, Los Angeles
2004-08 – 2008-08 · Substance-Related Disorders
What this study did
Phase 1 (19)
Epilepsy
NCT00114569 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005-03 – 2009-02 · Status Epilepticus
What this study did
Other / comorbidity
NCT07560878 · Mclean Hospital
2026-03-11 – 2030-12 · Major Depression
What this study did
NCT04923659 · University Health Network, Toronto
2021-05-25 – 2026-05 · Low Intensity Focussed Ultrasound
What this study did
NCT05964647 · University Hospital, Basel, Switzerland
2024-02-01 – 2025-06-30 · Healthy
What this study did
NCT03030417 · National Cancer Institute (NCI)
2017-02-27 – 2023-10-12 · Solid Tumors, Lymphoma
What this study did
NCT04671836 · Northwell Health
2022-01 – 2022-12 · Lorazepam, Neuroimaging
What this study did
NCT03829839 · University Hospital, Bonn
2016-03-03 – 2017-08-16 · Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
What this study did
NCT01780519 · Mayo Clinic
2013-01 – 2016-09 · Alzheimer's Disease (AD)
What this study did
NCT00881556 · Columbia University
2009-08-20 – 2015-09 · Epidermolysis Bullosa
What this study did
NCT02462109 · Makerere University
2013-03 – 2013-03 · Catatonia, Nodding Syndrome
What this study did
NCT01275144 · Eli Lilly and Company
2010-12 – 2011-02 · Major Depressive Disorder
What this study did
NCT01110616 · Merck Sharp & Dohme LLC
2010-06 – 2010-10 · Dementia
What this study did
NCT00055549 · National Institute of Neurological Disorders and Stroke (NINDS)
2003-03-04 – 2009-11-13 · Voice Disorders
What this study did
NCT00720421 · AstraZeneca
2008-06 – 2008-08 · Healthy Volunteer
What this study did
NCT00424697 · GlaxoSmithKline
2007-03 – 2007-12 · Healthy Subjects
What this study did
NCT00364429 · GlaxoSmithKline
2005-07 – 2005-07 · Schizophrenia
What this study did
NCT00649818 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did
Phase 4 (23)
Other / comorbidity
NCT06852469 · VA Office of Research and Development
2025-07-01 – 2029-06-30 · Stress Disorders, Post-Traumatic
What this study did
NCT07428681 · University Hospital, Basel, Switzerland
2027-03 – 2029-02 · Delirium Confusional State
What this study did
NCT06799494 · Emory University
2025-08-06 – 2028-09 · HPV
What this study did
NCT06004115 · Laureate Institute for Brain Research, Inc.
2023-11-08 – 2027-12-31 · Depression, Anxiety, Fear, Depression, Anxiety and Fear, Anxiety Disorders, Anxious Depression
What this study did
NCT04240626 · University of California, Davis
2021-01-20 – 2025-06-24 · Obesity, Morbid, Surgery, Bariatric Surgery Candidate
What this study did
NCT04004416 · University of Michigan
2020-01-16 – 2025-02-28 · Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
What this study did
NCT04156464 · OSF Healthcare System
2020-07-06 – 2022-03-01 · Alcohol Withdrawal, Alcohol Withdrawal Delirium
What this study did
NCT03090620 · University of Colorado, Denver
2017-03-30 – 2020-08-31 · Anticholinergics Toxicity
What this study did
NCT03202550 · Johns Hopkins University
2017-06-28 – 2019-05-28 · Oral Sedation and Cervical Dilator Pain
What this study did
NCT03788889 · Santa Barbara Cottage Hospital
2019-04-12 – 2019-04-12 · Alcohol Withdrawal Syndrome
What this study did
NCT02407704 · Kirk Erickson, PhD
2015-03 – 2016-12 · Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
What this study did
NCT01889602 · University of Minnesota
2013-07 – 2016-08 · Cognitive Deficits
What this study did
NCT01877642 · Alexza Pharmaceuticals, Inc.
2013-06 – 2013-07 · Healthy Volunteers
What this study did
NCT00721526 · University of New Mexico
2009-08 – 2012-08 · Alcohol Dependence, Anxiety Disorder
What this study did
NCT01330459 · Elizabeth Micks
2011-02 – 2011-10 · Pain
What this study did
NCT01441843 · Erasmus Medical Center
2010-10 – 2011-09 · Anxiety
What this study did
NCT01121055 · Seoul National University Hospital
2010-03 – 2010-12 · Patient Satisfaction for Bronchoscopy
What this study did
NCT00457366 · University of Southern California
2006-05 – 2009-05 · Agitation
What this study did
NCT00158873 · GlaxoSmithKline
started 2004-09 · Sedation
What this study did
NCT00044642 · Nathan Kline Institute for Psychiatric Research
2000-12 – 2007-07 · Anxiety Disorders, Generalized Anxiety Disorder
What this study did
NCT00159133 · Heinrich-Heine University, Duesseldorf
2001-11 – 2006-06 · Schizophrenia, Psychoses
What this study did
NCT00249366 · Virginia Commonwealth University
2001-04 – 2003-05 · Alcohol Withdrawal Syndrome
What this study did
NCT00000441 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
est. completion 2000-12 · Alcoholism
What this study did
Early phase / not applicable (15)
Other / comorbidity
NCT02863614 · University of Sao Paulo
2015-05 – 2017-05 · Subfertility, Infertility
What this study did
NCT01566539 · Emory University
2008-04 – 2016-11 · Healthy
What this study did
NCT01393288 · University of California, San Francisco
2013-11 – 2015-11 · Postoperative Nausea and Vomiting, Genetic Polymorphisms
What this study did
NCT02362256 · Vilnius University
2014-05 – 2014-09 · Opiate Addiction
What this study did
NCT03435692 · Seattle Children's Hospital
2011-07-15 – 2014-07-29 · Hip Surgery, Post Operative Pain Control
What this study did
NCT01204255 · Virginia Commonwealth University
2010-11-15 – 2011-05-17 · Healthy
What this study did
NCT01272778 · Orasi Medical, Inc.
2010-10 – 2011-04 · Healthy Subjects
What this study did
NCT00696033 · University Hospital, Strasbourg, France
2007-07 – 2008-12 · Healthy Subjects
What this study did
NCT00597701 · Essentia Health
2003-04 – 2008-02 · Alcohol Withdrawal Delirium
What this study did
NCT00337792 · Planned Parenthood League of Massachusetts
2006-06 – 2007-07 · Undesired Pregnancy
What this study did
NCT00586430 · Mayo Clinic
2005-12 – 2007-07 · Alzheimer's Disease
What this study did
NCT00846950 · Maastricht University Medical Center
2006-12 – 2007-05 · Cognition
What this study did
NCT00523185 · Stanford University
2003-05 – 2004-11 · Alcohol Withdrawal
What this study did
NCT00715039 · Pfizer
2003-10 – 2004-05 · Anxiety Disorders
What this study did
Used as active comparator (22)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Other / comorbidity
NCT06370442 · State University of New York - Upstate Medical University
2024-06-01 – 2025-09-01 · Altered Mental Status
What this study did
NCT01067144 · Stanford University
2010-05 – 2016-07 · Pain, Breast Cancer, Lung Cancer
What this study did
NCT02147548 · Biocodex
2013-12 – 2015-10 · Healthy Volunteers
What this study did
NCT00797277 · National Taiwan University Hospital
2006-07 – 2009-06 · Schizophrenia, Schizoaffective Disorder, Agitation
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06752616 · Lone Baandrup
2024-12-30 – 2027-12 · Agitation
What this study did
Phase 2 (4)
Epilepsy
NCT03021018 · UCB Biopharma S.P.R.L.
2017-02-06 – 2018-04-27 · Epilepsy
What this study did
NCT02564029 · Pfizer
2015-12-16 – 2017-02-07 · Reflex Epilepsy, Photosensitive
What this study did
Other / comorbidity
NCT04715230 · InterveXion Therapeutics, LLC
2021-06-30 – 2022-11-14 · Methamphetamine Intoxication (Disorder)
What this study did
NCT00807937 · AstraZeneca
2008-12 – 2009-05 · Anxiety Disorders
What this study did
Phase 1 (4)
Epilepsy
NCT00736931 · UCB Pharma
2008-07 – 2008-10 · Epilepsy
What this study did
Other / comorbidity
NCT03300947 · University of Arizona
2019-01-02 – 2023-12-30 · Obsessive-compulsive Disorder (OCD)
What this study did
NCT00902772 · AstraZeneca
2009-05 – 2009-09 · Recreational CNS Depressant Use
What this study did
NCT00750802 · AstraZeneca
2008-09 – 2008-12 · Healthy Volunteer
What this study did
Phase 4 (7)
Other / comorbidity
NCT06429657 · Henry M. Jackson Foundation for the Advancement of Military Medicine
2024-09-23 – 2027-06-30 · Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
What this study did
NCT05599126 · Zhenghui YI
2024-07-01 – 2025-12-30 · Depression
What this study did
NCT02078336 · Universitaire Ziekenhuizen KU Leuven
2013-12 – 2025-07 · Dental Care for Disabled
What this study did
NCT06093451 · Temple University
2023-07-01 – 2024-07-01 · Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
What this study did
NCT03110900 · University of Arkansas
2017-09-30 – 2018-04-04 · Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
What this study did
NCT02367755 · Far Eastern Memorial Hospital
2013-08 – 2016-12 · Hypothermia, Cardiac Arrest
What this study did
NCT00624780 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-05 – 2012-04 · Generalized Anxiety Disorder
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT01684085 · Sheba Medical Center
2012-10 – 2014-09 · Post Traumatic Stress Disorder, Sleep Deprivation
What this study did
NCT00641797 · Lehigh Valley Hospital
2006-11 – 2013-11 · Benign Paroxysmal Positional Vertigo
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Other / comorbidity
NCT03235531 · CAMC Health System
2017-07-11 – 2019-06-25 · Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
What this study did

Competitive landscape

This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lorazepam: this drugApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
KH607
Phase 3(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
CB03-154Phase 2Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
GlyphAllo (allopregnanolone Prodrug) (SPT-300)
Phase 2(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-10353
Phase 2(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Huperzine A (SPN-817)Phase 2Small moleculeAcetylcholinesteraseWeak signal
NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events.
NPT2042Phase 2Small moleculeNKCC1Partial signalNo reviewed efficacy summary in this indication
AMT-260Phase 1/2Gene therapy / editingGRIK2 (GluK2-containing kainate receptor)not yet gradedNo reviewed efficacy summary in this indication
ETX101Phase 1/2Gene therapy / editingSCN1A (transcriptional upregulation)not yet gradedNo reviewed efficacy summary in this indication
ION337Phase 1/2RNA / oligonucleotideSCN1A mRNAnot yet gradedNo reviewed efficacy summary in this indication
S230815Phase 1/2RNA / oligonucleotideKCNT1 mRNAnot yet gradedNo reviewed efficacy summary in this indication
iQ-007Phase 1Small moleculeEAAT2 (glutamate transporter, positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
Remimazolam
Phase 1(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 74 furthest-along competitors are listed; 3 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lorazepam to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 4Depression, Anxiety, Fear, Depression, Anxiety and Fear, Anxiety Disorders, Anxious DepressionRecruiting
Est. primary completion 2027-12-31 · NCT06004115 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 4Delirium Confusional StateNot yet recruiting
Est. primary completion 2028-02 · NCT07428681 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4HPVRecruiting
Est. primary completion 2028-09 · NCT06799494 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2/3Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant NeoplasmActive not recruiting
Est. primary completion 2028-12-31 · NCT03743649 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 4Stress Disorders, Post-TraumaticRecruiting
Est. primary completion 2029-06-30 · NCT06852469 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 1Major DepressionRecruiting
Est. primary completion 2030-12 · NCT07560878 · CT.gov ↗
What to watch

See the full readout calendar ↗